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Emergence of Aspergillus fumigatus strains contain-
ing mutations that lead to azole resistance has become a 
serious public health threat in many countries. Nucleotide 
polymorphisms leading to amino acid substitutions in the 
lanosterol demethylase gene (cyp51A) are associated with 
reduced susceptibility to azole drugs. The most widely rec-
ognized mutation is a lysine to histidine substitution at aa 
98 (L98H) and a duplication of the untranscribed promoter 
region, together known as TR34/L98H. This mechanism 
of resistance has been reported in Europe, Asia, and the 
Middle East, and is associated with resistance to all azole 
drugs and subsequent treatment failures. To determine 
whether isolates with this mutation are spreading into the 
United States, we conducted a passive surveillance–based 
study of 1,026 clinical isolates of A. fumigatus from 22 US 
states during 2011–2013. No isolates harboring the TR34/
L98H mutation were detected, and MICs of itraconazole 
were generally low.
Azole antifungal drugs are the first line of therapy against Aspergillus fumigatus, a common etiologic 
agent of aspergillosis. These drugs are used as empirical 
prophylaxis and as targeted therapy for invasive aspergil-
losis. Resistance to azole drugs has been associated with 
treatment failure and deaths in patients with aspergillosis. In 
the past 2 decades, azole resistance in A. fumigatus has been 
documented in many regions (1–7). The high prevalence of 
azole resistance in A. fumigatus has prompted the European 
Centre for Disease Prevention and Control to increase the 
risk level of this organism to a public health risk (8).
A common mechanism that confers resistance to azole 
drugs is a mutation in the lanosterol 14 α-demethylase 
gene that encodes the CYP51A protein. This protein is the 
primary target of azole drugs and sterol demethylation in-
hibitor (DMI) fungicides (9–11). However, not all cyp51A 
mutations contribute to azole resistance (some are benign), 
and not all azole resistance is caused by mutations in the 
cyp51A gene (12).
In the past decade, novel cyp51A promoter duplica-
tion mutations, especially the cooperative pair of cyp51A 
mutations known as TR34/L98H, have emerged as a pre-
dominant azole-resistance mechanism in A. fumigatus 
(1,4,6,10,11,13–22). Isolates harboring the TR34/L98H 
mutation are cross-resistant to multiple azoles (4,15,17). A 
second cyp51A-promoter duplication genotype, the recent-
ly discovered TR46/Y121F+T289A, also displays high tol-
erance for voriconazole (13,14). Both genotypes are asso-
ciated with in vitro MICs that exceed by multiple dilutions 
the established epidemiologic cutoff value (ECV) of ≤1 µg/
mL published by the European Committee on Antimicrobi-
al Susceptibility Testing and Clinical and Laboratory Stan-
dards Institute members for medical azole agents (9,13). 
Moreover, these mutations often contribute to failure of 
azole therapy in aspergillosis patients (13–23). Their pres-
ence rules out the use of voriconazole, the treatment rec-
ommended by the Infectious Diseases Society of America 
for aspergillosis, and leaves amphotericin B, an antifungal 
drug with toxic side effects, as the primary therapy choice.
Since the discovery of the TR34/L98H mutation in the 
Netherlands by Verweij et al. in 2007 (15), other countries 
in Europe, including Austria, Belgium, Germany, Spain, 
France, the United Kingdom, Denmark, and Norway, have 
also reported isolates harboring TR34/L98H (5,7,16–20,24). 
A. fumigatus isolates with the TR34/L98H mutation have 
also been reported in China, India, and Iran (1,4,6,21). 
Because of rapid increase in detection of the TR34/L98H 
mutation in many regions and its adverse effect on patient 
management, isolates harboring this mutation pose a seri-
ous public health threat. Isolates bearing the TR34/L98H 
mutation have not been documented in United States, but 
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given the number of aspergillosis cases in this country, its 
presence could pose a serious public health threat, as it 
does in Europe.
The TR34/L98H mutation is not associated with use of 
long-term medical azole therapy in patients. Instead, pro-
longed exposure of the fungus to sterol DMI fungicides 
in the environment, in conjunction with sexual reproduc-
tion, has probably led to dissemination of this mutation 
(19,25). As in many countries in which this genotype has 
been reported, DMI fungicides are used in various agricul-
tural practices across the United States. According to the 
US Department of Agriculture data for 2010–2013, DMI 
fungicides, such as tebuconazole, propiconazole, prothio-
conazole, tetraconazole, metconazole, and epoxiconazole, 
have been used by several agricultural producers (26). This 
shared agriculture practice indicates that the TR34/L98H 
mutation could potentially arise in the United States.
Thus, the Centers for Disease Control and Prevention 
initiated passive surveillance for A. fumigatus isolates in 
2011 to identify resistance to the representative azole itra-
conazole. More than 1,000 clinical isolates from 22 states 
were screened by using an itraconazole antifungal plate 
assay and the Etest to measure itraconazole MICs. For 
isolates that require an MIC greater than the ECV, DNA 
sequence analysis of the cyp51A gene did not yield any iso-
lates with the TR34/L98H genotype.
Materials and Methods
Fungal Isolates
A. fumigatus isolates were obtained through the 
American Society for Microbiology listservs (DivC) and 
(ClinMicroNet) (http://www.asm.org/index.php/online-
community-groups/listservs) and through the US Associa-
tion of Public Health Laboratories. The request for isolates 
read as follows: “To determine the US level of A. fumigatus 
azole resistance, we are requesting submission of: 1) All 
new or stored isolates of Aspergillus fumigatus from US 
collections; 2) Any new isolates of A. fumigatus regardless 
of clinical relevance.” Isolates were sent to the Centers for 
Disease Control and Prevention where the species was con-
firmed by colony color and morphologic features observed 
by microscopy. Cryptic species that required increased 
MICs were subsequently ruled out by DNA sequencing of 
the cyp51A gene as described below.
Itraconazole Susceptibility Assay
All isolates were screened by using 2 methods: antifun-
gal plate culture and itraconazole Etest (bioMérieux, Marcy 
l’Etoile, France). For plate culture, a 24-well culture plate 
containing 1 mL of Sabouraud agar supplemented with 4 µg/
mL of itraconazole was used. Twenty microliters of a sus-
pension containing ≈ 2 × 104 conidia were transferred to each 
well and allowed to dry at ambient temperature for 30 min 
before incubation. Etest determination of itraconazole MICs 
was performed as described by Pfaller et al. (27) with minor 
modifications. Isolates of A. fumigatus were allowed to spor-
ulate on potato dextrose agar slants for 5–7 days. Conidial 
suspensions were prepared in sterile distilled water contain-
ing 1% Tween-20. The concentration was adjusted to an opti-
cal density of 0.09–0.13 or ≈106 conidia/mL equivalent at 530 
nm. An RPMI 1640 agar plate was inoculated by streaking a 
conidia-laden cotton swab bidirectionally across the surface 
of the plate. An itraconazole Etest strip was placed across 
the central surface of the freshly inoculated RPMI plate. An 
azole-resistant and an azole-susceptible isolate for which 
broth microdilution azole MICs were known were used as 
controls (1). The Etest and itraconazole plates were incubated 
at 37°C, and results were recorded 48 hours postinoculation.
Genetic Profiling of cyp51A
DNA sequence analysis of the cyp51A gene and its pro-
moter region was performed for all isolates that required an 
MIC above the ECV (1 µg/mL) by using primers described 
(1). A subset of the first 561 isolates was also examined by 
using a mixed-format real-time PCR to detect nucleotide 
polymorphisms that cause single amino acid substitutions 
at Gly54, Leu98, Gly138, and Met220, and the recently 
discovered TR46/Y121F/T289A in the CYP51A protein as 
described by Klaassen et al. (28).
A. fumigatus genomic DNA was purified by using the 
DNeasy blood and tissue kit (QIAGEN, Valencia, CA, 
USA) with some modifications. Hyphae were transferred 
to a 1.5-mL microcentrifuge tube containing 360 mL of Z-
buffer (29) (60 mmol/L Na2HPO4, 40 mmol/L NaH2PO4, 
10 mmol/L KCl, 1 mmol/L MgSO4, 38 mmol/L b-mercap-
toethanol, pH 7) and 40 mL of proteinase K (QIAGEN). 
A total of 250 mg of 0.5-mm zirconia beads (BioSpec, 
Bartlesville, OK, USA) was added to the cell suspension, 
and cells were homogenized for 1 min at maximum speed 
by using a mini-beadbeater (BioSpec). Four hundred mi-
croliters of AL buffer (QIAGEN) was added to the cell 
lysate and mixed by vortexing for 10 s. The lysate was 
then centrifuged at 13,200 rpm for 5 min. The supernatant 
was transferred to a clean 1.5-mL microcentrifuge tube, 
and an equal volume of absolute ethanol was added to the 
supernatant. After briefly undergoing vortexing, the DNA 
suspension was transferred to a spin column (QIAGEN). 
DNA binding, washes, and elution steps were followed as 
described by the manufacturer.
Results
Characteristics of A. fumigatus Isolates
A request for A. fumigatus clinical isolates collected 
beginning in 2011 was initiated in June 2011. Because the 
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TR34/L98H mutation was believed to be environmentally 
induced, all A. fumigatus clinical isolates were accepted, 
not just those causing infection. A total of 1,026 clinical 
isolates were obtained during September 2011–September 
2013 from hospitals, clinics, and state public health labo-
ratories across 22 states (Figure 1), including Arizona (n = 
17), California (n = 139), Connecticut (n = 140), Florida 
(n = 78), Georgia (n = 133), Iowa (n = 56), Illinois (n = 
111), Indiana (n = 13), Kansas (n = 3), Massachusetts (n 
= 2), Maine (n = 52), Michigan (n = 105), Minnesota (n = 
84), Missouri (n = 7), Montana (n = 6), North Carolina (n 
= 9), New York (n = 15), Oregon (n = 35), Tennessee (n = 
5), Texas (n = 8), Virginia (n = 1), Wyoming (n = 1), and 
unknown (n = 7). The isolates were form respiratory tracts 
(≈57%), ears (≈4%), other tissues (≈5%), and unknown 
sources (≈34%). Of respiratory tract isolates, 65% were 
collected from sputum and 25% from bronchoalveolar la-
vage specimens.
Most A. fumigatus isolates were susceptible to itracon-
azole. Historically, the TR34/L98H mutation has been de-
tected by itraconazole plate assay. We also used the Etest 
validate its utility for detecting high MICs. The same 3 iso-
lates were identified by their growth on the itraconazole 
plate and an itraconazole Etest MIC >4 µg/mL, which in-
dicated congruence for the 2 tests. Overall MICs ranged 
from 0.05 µg/mL to 32 µg/mL, and 95% of the isolates 
required an MIC ≤1 µg/mL) (Figure 2). The 50% MIC 
(MIC50,), MIC90, and MIC mode for isolates were 0.5 µg/
mL, 1.0 µg/mL, and 0.5 µg/mL, respectively. Of 51 isolates 
that required an increased MIC for itraconazole, >94% (n 
= 48) required an MIC <4 µg/mL and were negative by 
agar screening, and 3 isolates required MICs of 6 µg/mL 
(n = 1), 16 µg/mL (n = 1), or ≥32 µg/mL (n = 1), the maxi-
mum value on the Etest strip.
Genetic Analysis of the cyp51A Gene
DNA sequence analysis of the cyp51A gene was per-
formed for 51 isolates that required an itraconazole MIC 
>1 µg/mL and for 36 isolates that required an itraconazole 
MIC ≤1 µg/mL. The duplication mutations (TR34 and TR46) 
in the promoter region of cyp51A and the L98H or Y121F/
T289A substitutions in cyp51A were not detected. Eighteen 
(35%) of the 51 isolates that required an increased MIC 
had a cyp51A mutation. The most common mutation in this 
group was a novel valine→isoleucine substitution at resi-
due 242 (I242V), which was found in 13 of the isolates that 
required increased MICs and 2 of the control isolates; all 
required MICs ≤4 µg/mL. There was also a set of 4 linked 
mutations in 2 of the control isolates that are commonly 
seen in susceptible isolates (1,3). The only mutation found 
that has been associated with azole treatment failure was an 
M220I mutation in the isolate that required an MIC ≥32 µg/
mL. A mixed-format real-time PCR was also used to screen 
the first 561 isolates collected for other known resistance-
inducing cyp51A single nucleotide polymorphisms. Except 
for the M220I mutation, no other polymorphisms were 
identified by using this method.
Discussion
Azoles, specifically voriconazole and (in some in-
stances) itraconazole, are the recommended treatment for 
aspergillosis (30). These drugs have a high potency against 
the most common causes of aspergillosis (i.e., A. fumiga-
tus, A. niger, A. flavus, and A. terreus). However, reduced 
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Figure 1. Distribution of 
Aspergillus fumigatus iso-
lates, United States, 2011–
2013. A total of 1,026 clinical 
isolates were received from 
22 states during October 
2011–October 2013.
Azole-Resistant A. fumigatus, USA, 2011–2013
susceptibility to these drugs has been reported (3,7,15,18). 
Many triazole-resistant isolates from aspergillosis patients 
who showed treatment failure with triazole therapy have 
mutations within the CYP51A protein (31–35), but this is 
not the only mechanism of resistance. The ECV was estab-
lished to define the limits of the wild-type distribution of 
MICs. It does not define a breakpoint but it may help iden-
tify isolates harboring mutations. In A. fumigatus, 2%–20% 
of isolates, depending on the country, require  MICs above 
the established ECVs for azoles (2–4,31,32,36). In this 
study, ≈5% of the isolates required an MIC greater than the 
established ECV for itraconazole. Isolates with no cyp51A 
mutations but which require high azole MICs are not un-
common. The mechanisms of resistance in these isolates 
are not precisely known but are assumed to be changes in 
drug transporter pumps (37,38).
Azole resistance is typically associated with cyp51A 
mutations, especially the TR34/L98H and TR46/Y121F/
T289A dual mutations. A total of 26%–94% of azole-resis-
tant isolates, especially in the Netherlands, have these mu-
tations (1,15,20,31). However,  we found no isolates har-
boring the TR34/L98H mutation in this study. One isolate 
was found to have an amino acid substitution at M220 and 
an itraconazole MIC ≥32 µg/mL. Amino acid substitutions 
at the M220 residue in A. fumigatus have been shown to 
confer resistance to all 3 mold-active azoles and are known 
to be induced by prolonged use of azoles in individual pa-
tients (39). Another common mutation that was discovered 
in isolates that required increased MICs for itraconazole 
is I242V. The MIC required for isolates with this muta-
tion ranges from 1 µg/mL to 4 µg/mL. There have been no 
reports linking this mutation to azole resistance and a rela-
tionship between this mutation and azole resistance has not 
been demonstrated experimentally. The mechanism caus-
ing increased MICs for other isolates is not known, a com-
mon problem for researchers working on drug resistance in 
Aspergillus spp. (3,32).
Genetic mutations in A. fumigatus cyp51A are be-
lieved to be associated with exposure to azole compounds 
(19,34,37,39). The TR34/L98H and TR46/Y121F/T289A 
mutations specifically are believed to have originated 
from exposure to DMI fungicides in the environment 
(10,13,14,25). According to the US Department of Agri-
culture, agricultural producers in the United States use a 
lower tonnage of DMI fungicides than their counterparts 
in Europe and Asia (26). During 2010–2012, combined 
DMI fungicide use from states that provided isolates for 
this study was 381,018 kg. Of these states, California was 
the highest user (84,051 kg). According to the European 
Centre for Disease Prevention and Control, the United 
Kingdom used 271,124 kg of DMI fungicides during 2006–
2009 (8). Therefore, the observed low rate of cyp51A muta-
tion–dependent resistance, specifically the absence of TR34/
L98H and TR46/Y121F/T289A mutations in this study than 
in studies from countries in Europe, Asia, and the Middle 
East, might be caused by differences in the extent of A. 
fumigatus exposure to DMI fungicides. The low rate of re-
sistance in A. fumigatus shown is supported by results of 
other smaller studies in the United States (2,40).
There were several limitations to our study. First, 
isolates were collected passively. Some areas of the Unit-
ed States were overrepresented and others, such as the 
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Figure 2. Itraconazole susceptibility 
profile for Aspergillus fumigatus 
isolates, United States, 2011–2013. 
The MIC (µg/mL) required by each 
isolate was determined by using the 
Etest method. Approximately 5% of 
the isolates require an MIC higher 
than the established epidemiologic 
cutoff value of 1 µg/mL.
RESEARCH
Midwest, were underrepresented. If the TR34/L98H mu-
tation is found only in isolates from specific localities in 
the United States, it might have been missed during this 
surveillance. Second, all isolates were accepted. If surveil-
lance was aimed specifically at isolates from patients who 
showed therapy failure, there may have been few isolates 
but those received might have demonstrated a greater prev-
alence of cyp51A mutations. Third, because isolates were 
received without personal identifiers and little meta data, 
there was no way of knowing whether multiple isolates 
came from 1 person.
In conclusion, this surveillance study indicates that the 
TR34/L98H mutant A. fumigatus that is now found through-
out Europe has not yet emerged in the United States. Ap-
proximately 5% of A. fumigatus isolates from the United 
States required increased MICs for itraconazole, but most 
isolates did not have a detectable genetic mutation. In light 
of increasing reports of TR34/L98H-mediated and other 
cyp51A-mediated drug resistance in Europe and Asia, fur-
ther surveillance is warranted.
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